CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Acadia Pharmaceuticals Q3 revenue rises 23% on DAYBUE and NUPLAZID sales

By Reuters News


Overview

  • Neurology drugmaker's Q3 revenue rose 23% yr/yr, driven by DAYBUE and NUPLAZID sales

  • DAYBUE Q3 net sales up 39% yr/yr; NUPLAZID sales up 14% yr/yr

  • Company raised 2026 DAYBUE sales guidance and narrowed total revenue and NUPLAZID ranges


Outlook

  • Company revises 2026 total revenue guidance to $1.265–$1.295 bln from $1.24–$1.30 bln

  • DAYBUE 2026 net sales guidance raised to $505–$520 mln from $480–$510 mln

  • NUPLAZID 2026 net sales guidance narrowed to $760–$775 mln from $760–$790 mln


Result Drivers

  • DAYBUE STIX UPTAKE - Co said strong uptake of DAYBUE STIX drove 39% yr/yr growth in DAYBUE sales

  • NUPLAZID DEMAND - Co attributed NUPLAZID sales growth to underlying demand and expanded commercial reach

  • EUROPEAN LAUNCH - Co cited initial momentum from DAYBU launch in Germany as contributing to results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenues

$342.29 mln

Q3 EPS

$0.31

Q3 Net Income

$53.52 mln

Q3 Operating Expenses

$270.57 mln

Q3 Pretax Profit

$80.44 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Acadia Pharmaceuticals Inc. is $31.92, about 55.2% above its November 3 closing price of $20.57

  • The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 40 three months ago


Reuters Recommended Reads

  • Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

  • Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

  • Nov 3 - Amgen Q3 revenue beats expectations on higher volumes


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.